Gelomics

Gelomics revolutionises drug development by enabling pharmaceutical companies to grow functional human tissues in a petri dish—delivering superior preclinical predictivity, accelerating time to market, and replacing animal testing with a scalable, ethical alternative. Named KPMG’s Australian Tech Innovator 2024, the company has bootstrapped through MVP development, raised over $4 million in venture and non-dilutive funding, and validated its platform with more than 300 paying customers across 23 countries, achieving an 80% demo-to-sales conversion rate. Gelomics is now raising its 2025 Seed round to launch next-generation products and expand into the US market.